Hunan Province Tumor Hospital — CureCurrent

Published trials66

Recruiting shown16

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerNCT07251582 · lead sponsor · 2026-08-12

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLCNCT06348927 · lead sponsor · 2024-07-01

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RWNCT06355609 · lead sponsor · 2024-07-01

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKNCT05266846 · lead sponsor · 2024-05-29

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal MetastasesNCT06440954 · lead sponsor · 2024-05-01

The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLCNCT06109558 · lead sponsor · 2023-12-31

Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision RadiotherapyNCT05584267 · lead sponsor · 2022-12-25

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung CancerNCT05284539 · lead sponsor · 2022-04-01

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell CarcinomaNCT05014464 · lead sponsor · 2021-11-13

Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung CancerNCT05059951 · lead sponsor · 2021-10-03

Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint InhibitorsNCT05055908 · lead sponsor · 2021-10-01

The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.NCT04777084 · lead sponsor · 2021-08-01

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic MutationNCT04322890 · lead sponsor · 2020-04-16

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLCNCT04324164 · lead sponsor · 2020-03-24

Anlotinib Plus Immune Checkpoint Inhibitors for Lung CancerNCT04322617 · lead sponsor · 2020-03-24

Survival Outcomes of Lung CancerNCT03647098 · lead sponsor · 2018-08-01

Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLCNCT06706219 · lead sponsor · 2026-05-10

NOT_YET_RECRUITING

Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI ProgressionNCT07001995 · lead sponsor · 2026-05-01

NOT_YET_RECRUITING

Megestrol Acetate for First-Line Treatment of Malnourished Non-Small Cell Lung CancerNCT07477808 · lead sponsor · 2026-04-01

NOT_YET_RECRUITING

The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung CancerNCT06477055 · lead sponsor · 2025-12-02

Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung CancerNCT06828757 · lead sponsor · 2025-05-01

NOT_YET_RECRUITING

Third-generation EGFR-TKI Plus Anlotinib as Maintenance for NSCLC With Small Cell Transformation After EGFR-TKI ResistanceNCT06634667 · lead sponsor · 2024-11-30

NOT_YET_RECRUITING

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges MetastaticNCT06497543 · lead sponsor · 2024-10-01

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal MetastasesNCT06537297 · lead sponsor · 2024-09-30

Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway ObstructionNCT06604351 · lead sponsor · 2024-09-15

NOT_YET_RECRUITING

A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung CancerNCT05991193 · lead sponsor · 2023-12-29

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLCNCT05991206 · lead sponsor · 2023-12-25

Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung CancerNCT05991180 · lead sponsor · 2023-12-25

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLCNCT05296278 · lead sponsor · 2023-12-25

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung CancerNCT04951947 · lead sponsor · 2023-06-01

Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIBNCT05295212 · lead sponsor · 2023-02-01

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLCNCT05549037 · lead sponsor · 2022-09-23

To Evaluate the Correlation Between the Results of Specific Gene Testing and the Efficacy of Targeted Therapy in Patients With NSCLCNCT05805267 · lead sponsor · 2022-09-20

Association Between the Results of Specific Genetic Tests and the Efficacy of Targeted Therapies in PatientsNCT05450081 · lead sponsor · 2022-06-30

High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) MetastasesNCT05379803 · lead sponsor · 2022-05-01

Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung CancerNCT05296603 · lead sponsor · 2021-12-03

Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLCNCT04997382 · lead sponsor · 2021-08-17

SHR-1701 Combined With Fluzoparib in Lung Squamous Cell CarcinomaNCT04937972 · lead sponsor · 2021-07-01

Efficacy of Osimertinib in Patients With Lung CancerNCT06174857 · lead sponsor · 2021-01-01

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON TrialNCT04322591 · lead sponsor · 2020-03-24

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLCNCT04324125 · lead sponsor · 2020-03-24

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLCNCT04322578 · lead sponsor · 2020-03-24

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLCNCT04324151 · lead sponsor · 2020-03-24

A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung CancerNCT06183762 · lead sponsor · 2020-01-01

Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung CancerNCT05055999 · lead sponsor · 2019-04-01

Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung CancerNCT05055947 · lead sponsor · 2019-04-01

Phase II Study on Sintilimab Combined With Docetaxel for Chemotherapy Failure Advanced NSCLC: the SUCCESS StudyNCT03798743 · lead sponsor · 2019-01-01

Consistency of PD-L1 Detecting Method Between E1L3N and 22C3 Monoclonal Antibodies in NSCLC PatientsNCT05129462 · lead sponsor · 2018-08-05

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung CancerNCT03646994 · lead sponsor · 2018-08-01

Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung CancerNCT03647592 · lead sponsor · 2018-06-01

The Prediction Biomarkers of Survival Outcome for Severe Immune-related HepatitisNCT05326906 · lead sponsor · 2018-05-01

Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological TypeNCT05023837 · lead sponsor · 2018-03-02

Local Radiotherapy for Residual Tumor Lesions During the First-line TreatmentNCT05205226 · lead sponsor · 2018-01-02

Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung CancerNCT03647111 · lead sponsor · 2018-01-01

Outcomes With Immune Checkpoint Inhibitor for Patients With Non-Small-Cell Lung Cancer and Stable Brain MetastasesNCT05129202 · lead sponsor · 2017-11-03

Intensity-modulated Radiotherapy (IMRT) With Simultaneous Integrated Boost (SIB) for Inoperable Non-small-cell Lung CancerNCT02841228 · lead sponsor · 2015-11-01

Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung AdenocarcinomaNCT02399566 · lead sponsor · 2015-05-01

Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung CancersNCT02098954 · lead sponsor · 2014-07-01

Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung CancersNCT02166242 · lead sponsor · 2014-06-01

Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung CancersNCT02161991 · lead sponsor · 2014-02-01

Sponsor roles

lead sponsor65

collaborator1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.